A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
Status:
Completed
Trial end date:
2020-02-27
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blind, Parallel-group, Three-arm, Placebo-controlled, Multi-Site
Therapeutic Equivalence Study with Clinical End-points Comparing Test Product "Oxymetazoline
hydrochloride Cream, 1%" to Reference Product "RHOFADE™ Cream, 1%" in the Treatment of
Moderate to Severe Persistent Facial Erythema of Rosacea